Psyence Group has completed an export of psilocybin to Psilo Pharma from its federally licensed ISO22000 certified production facility in Southern Africa, through its research partner in Portugal.
With the advancement of psilocybin-based research for understanding how the substance could benefit mental ill health, a high-quality supply of medical-grade psilocybin is needed for research and clinical trials.
In February 2022, Psyence received an import permit from the Portuguese regulators for the research partner in Portugal. It obtained the necessary, stringent permissions to commence with the export process and the psilocybin mushrooms were successfully delivered to the research partner’s facilities.
Psilo Pharma, which aims to provide the highest quality psilocybin across Europe, will be using the mushrooms to develop extraction methodologies.
CEO of Psilo Pharma, David Reckeweg-Lecompte, commented: “Our approach to this extremely promising healthcare segment is to (i) provide the highest quality API, (ii) supply clinical trials for drug development, and (iii) engage in development partnerships.
“We are preparing for the eventual commercialisation of psilocybin as a crucial component for an alternative and superior treatment of mental health.
“In Portugal, our goal is to establish proprietary extraction methods and procedures for naturally produced psilocybin.”
Psyence CEO, Dr Neil Maresky, commented: “The export of Psyence’s psilocybin mushrooms to Psilo Pharma’s research partner in Portugal is our first export to Europe and our second successful export to date.
“We are delighted that we have concluded two important exports as we aim to be a trusted, commercial supplier of psilocybin mushrooms for the legal, global medical market and commercial medical research market.
“Psyence’s ISO22000 certified production facility is fully operational, and we are able to ramp up production in line with demand from our customers and the global medical research market.”
Psyence operates one of the first federally licensed commercial psilocybin production facilities in the world. Its production facility, located in Southern Africa, is ISO22000 certified and is licensed to cultivate and export psilocybin mushrooms for the legal, global medical market and commercial medical research market.
Psyence’s cultivation system is designed for continuous harvesting and an on-site laboratory was recently added to provide in-process analysis and extraction.
